Welcome to TransTracheal Technologies . . .

Transtracheal oxygen is the only available means of home oxygen delivery that provides true 24-hour compliance. It is also
about twice as efficient as nasal cannulae and provides therapeutic reserve for ambulation and increased oxygen requirements.
Noncompliance with nasal cannulae is the norm, and the cumulative effects of chronic and intermittent hypoxemia result in unacceptable morbidity and mortality. The 2011 General Accounting Office report Medicare Payment for Home Oxygen found that "less than 25 percent
of beneficiaries reach the 36 month rental cap" (GAO-11-56, p.14). The clinical outcomes of the NOTT (n=203), MRC trial (n=87) and this
GAO report (n>600,000) justify a conclusion that oxygen delivered by nasal prongs is inadequate therapy. Clinical studies of transtracheal oxygen therapy instituted early in the course of various lung diseases show significantly less morbidity and increased longevity, and many transtracheal oxygen patients are stable after a decade on oxygen. Some are doing well after more than two decades.

                                                                (LINK)                  Oxygen is good!